Evidence map›Paper›PMID 35981900›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Antigen-Dependent Inducible T-Cell Reporter System for PET Imaging of Breast Cancer and Glioblastoma.

Jaehoon Shin, Matthew F L Parker, Iowis Zhu, Aryn Alanizi, Carlos I Rodriguez, Raymond Liu, Payal B Watchmaker, Mausam Kalita, Joseph Blecha, Justin Luu and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Synthetic Cells and Molecules in Cellular Immunotherapy.International journal of biological sciences · 2024
    Review
  5. Article
  6. Visualizing cell-cell communication using synthetic notch activated MRI.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Jaehoon ShinDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Matthew F L ParkerDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Iowis ZhuDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, California.
Aryn AlaniziDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Carlos I RodriguezDepartment of Pathology, University of California, San Francisco, San Francisco, California.
Raymond LiuDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, California.
Payal B WatchmakerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Mausam KalitaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Joseph BlechaDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Justin LuuDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Brian WrightDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama.
Suzanne E LapiDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama.
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Hideho OkadaParker Institute for Cancer Immunotherapy, San Francisco, California.
Thea D TlstyDepartment of Pathology, University of California, San Francisco, San Francisco, California; david.m.wilson@ucsf.edu kole.roybal@ucsf.edu thea.tlsty@ucsf.edu.
Kole T RoybalDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, California; david.m.wilson@ucsf.edu kole.roybal@ucsf.edu thea.tlsty@ucsf.edu.
David M WilsonDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California; david.m.wilson@ucsf.edu kole.roybal@ucsf.edu thea.tlsty@ucsf.edu.
University of California, San Francisco · USParker Institute for Cancer Immunotherapy · USUniversity of Alabama at Birmingham · USChan Zuckerberg Initiative (United States) · USNeurological Surgery · USUCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

MOLECULAR AND CELLULAR IMMUNOLOGYT32AI007334 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1988 to 2023
$11.0M
Preclinical development of breakthrough immunotherapy for brain tumorsR35NS105068 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2018 to 2025
$6.0M
Development of 11C-PABA as a bacteria-specific imaging agent for spinal infectionsR01EB025985 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAIN, SANJAY, WILSON, DAVID M · 2018 to 2021
$2.7M
Sensing living P. aeruginosa using D-alanine derived radiotracersR01EB030897 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ENGEL, JOANNE N., OHLIGER, MICHAEL · 2021 to 2024
$2.7M
ACE2-targeted PET radiotracers for investigating spatiotemporal distribution of SARS-CoV-2 organ injury and therapy response.R01AI161829 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DESAI, TEJAL A., FLAVELL, ROBERT RICHARD · 2021 to 2023
$2.4M
Clinical translation of D-amino acid derived PET tracers for imaging spinalinfectionR01EB024014 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OHLIGER, MICHAEL, WILSON, DAVID M · 2017 to 2020
$2.2M
Next-generation Ligand-dependent Transcriptional Switch Receptors for the Control and Customization of Cell TherapeuticsF30CA250247 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZHU, IOWIS · 2020 to 2023
$180k
NCI NIH HHS F30 CA250247NIAID NIH HHS R01 AI161829NIAID NIH HHS T32 AI007334NIBIB NIH HHS R01 EB024014NIBIB NIH HHS R01 EB025985NIBIB NIH HHS R01 EB030897NINDS NIH HHS R35 NS105068
6 · The paper itself

Abstract

For the past several decades, chimeric antigen receptor T-cell therapies have shown promise in the treatment of cancers. These treatments would greatly benefit from companion imaging biomarkers to follow the trafficking of T cells in vivo.

Indexed as

Breast NeoplasmsGlioblastomaAnimalsCell Line, TumorFemaleGenes, ReporterHumansPositron-Emission TomographyT-Lymphocytescancer antigensCAR TPETreporterSNIPR

Identifiers

PMID35981900
PMCPMC9841254
OpenAlexW4293805217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.